| Purpose of the guideline: |
In 2019, the Endocrinology Branch of the Chinese Medical Association released the 2019 Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout. The emergence of the 2019 Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout ultimately led to 52 clinical issues. Using WeChat survey questionnaire format, 620 questionnaires were distributed, covering 27 provinces, autonomous regions, municipalities directly under the central government, and special administrative regions. 620 questionnaires were collected, with an effective rate of 100%. After statistical sorting, 21 clinical questions were finally identified and integrated into 19 questions to be included in the content of this guideline. Out of the final 19 clinical questions, 1 was not included due to lack of evidence, and the remaining 18 questions were merged into 12, resulting in a total of 51 recommended opinions. The selection of drugs for acute gout attacks, the selection of uric acid lowering drugs for gout patients with hyperuricemia, the selection of uric acid lowering drugs for patients with chronic kidney disease, and the selection of drugs related to hyperuricemia and gout comorbidities are partially or entirely recommended. The evidence level is C or lower, and attention should be paid to this update. As a clinical issue of concern to clinical doctors, it existed in the initial 19 question list, but was not included in the 2019 guideline generation due to the lack of any systematic evaluation and guidelines for reference. In the following five years, a large number of basic research, clinical research, and epidemiological research results urgently need to be promoted to improve the understanding and standardized diagnosis and treatment of this group of diseases among clinical physicians. At the same time, the methods for developing clinical guidelines are becoming increasingly scientific, standardized, and internationalized. Therefore, the society has decided to update the diagnosis and treatment guidelines for HUA and gout in the Chinese endocrinology profession with standardized evidence-based medicine methods and processes based on the 2019 guidelines. |
